Verisk Names Saurabh Khemka President of Underwriting Solutions

(NASDAQ:VRSK), JERSEY CITY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) — Verisk (Nasdaq: VRSK), a leading strategic data analytics and technology partner to the global insurance industry, today announced that Saurabh Khemka has been named president of Underwriting Solutions, effective immediately. “Saurabh has been a great partner to our underwriting clients and has repeatedly used their […]

Weatherford Hosts FWRD 2025 Digital Conference, Showcasing Next-Generation Energy Technologies

(NASDAQ:WFRD), HOUSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) — Weatherford International plc (NASDAQ: WFRD) (“Weatherford” or the “Company”) today announced its flagship FWRD 2025 Conference, taking place September 30 – October 1 at the JW Marriott in Houston. The event convenes energy leaders, technology innovators, and technical experts from across the sector to exchange insights on

Innerflo Expands Beyond Stress Relief With New Focus and Productivity Features

VILNIUS, Lithuania, Sept. 30, 2025 (GLOBE NEWSWIRE) — Innerflo.me started as a simple solution to manage stress, but the latest update introduces new features designed to improve productivity and concentration. Users will not only be able to begin with stress-relief sessions but also choose “focus” option. All subscribers will gain access to both categories, making

OSS Announces Pricing of $12.5 Million Registered Direct Offering of Common Stock

OSS Announces Pricing of $12.5 Million Registered Direct Offering of Common Stock GlobeNewswire September 30, 2025 ESCONDIDO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (“OSS” or the “Company”) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) and sensor processing at the edge, today

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

Artelo Biosciences Announces Pricing of $2.0 Million Public Offering GlobeNewswire September 30, 2025 SOLANA BEACH, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of its

ZOOZ Completes Initial Purchase of ₿525 Valued at $60 Million, Becomes the First Dual-listed (Nasdaq and TASE) Company to Launch a Bitcoin Treasury Reserve Strategy

ZOOZ Completes Initial Purchase of â‚¿525 Valued at $60 Million, Becomes the First Dual-listed (Nasdaq and TASE) Company to Launch a Bitcoin Treasury Reserve Strategy GlobeNewswire September 30, 2025 Subsequent Closing of PIPE follows shareholder approval ZOOZ has begun using proceeds to acquire bitcoin, advancing on its path to becoming an institutional-scale, global bitcoin treasury

Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market

Branded Legacy, Inc. Announces Provisional Patent Filing by BioLegacy for Disruptive Air-Driven Intranasal Platform Targeting Multi-Billion-Dollar Global Therapeutics Market Revolutionary platform aims to make life-saving overdose reversal therapies more affordable, accessible, and effective worldwide GlobeNewswire September 30, 2025 VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) — via IBN — Branded Legacy, Inc. (OTC: BLEG),

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and Overall Survival GlobeNewswire September 30, 2025 FLORHAM PARK,

SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update

SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update GlobeNewswire September 30, 2025 NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ:

Scroll to Top